Navigation Links
New Ovarian Cancer Biomarker Research Act Introduced
Date:10/2/2007

Funding, Research and National Trials Crucial in the Fight Against Women's

Cancers

WASHINGTON, Oct. 2 /PRNewswire-USNewswire/ -- The Ovarian Cancer Biomarker Research Act of 2007 was introduced in the U.S. House of Representatives on Thursday, Sept. 27 and the Society of Gynecologic Oncologists (SGO), the leader of four organizations integral in drafting this legislation, is issuing a "call to action" for ovarian cancer survivors, their families, and their physicians.

Introduced by Congressmen Howard L. Berman (D-CA) and Ralph M. Hall (D-TX), the Ovarian Cancer Biomarker Research Act would authorize the National Cancer Institute (NCI) to make grants to public or non-profit entities for the establishment of research centers focused on ovarian cancer biomarkers. Biomarkers are the biochemical features within the body that can be used to determine the presence and population of cancerous cells, predict response to therapy, and determine ultimate prognosis. Additionally, the Ovarian Cancer Biomarker Research Act will also establish a national clinical trial to determine the clinical utility of ovarian cancer biomarkers in diagnosing or preventing ovarian cancer in at-risk women.

SGO, which is the professional organization for gynecologic oncologists, specialists in women's cancers, collaborated with the American College of Obstetricians and Gynecologists (ACOG), the Ovarian Cancer National Alliance, and the American College of Surgeons (ACS) to spearhead the development of the Ovarian Cancer Biomarker Research Act in order to secure dedicated support for ovarian cancer biomarkers research. Currently, a widely accepted or effective screening test for ovarian cancer is not available -- making the disease difficult to diagnose.

"Early diagnosis is critical," said Beth Karlan, MD, Director of the Cedars-Sinai Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute and an expert in the field of gynecologic oncology, ovarian cancer surgery, and inherited cancer susceptibility. "Women have just recently been made aware of the symptoms of ovarian cancer, but many of these symptoms can be easily confused with those of other diseases. Development of an effective biomarker screening test is imperative to saving the lives of women with ovarian cancer."

"What we need now is wide-spread action," adds Carol Brown, MD, a gynecologic oncologist at Memorial Sloan-Kettering Cancer Center and SGO's Government Relations Committee Chair. "The bill has been introduced, but it hasn't been passed yet. We are so appreciative that the Ovarian Cancer Biomarker Research Act has come this far, and we are grateful for the help and support we have received from Congressmen Berman and Hall, but we need to make sure that that this bill is passed. We need every woman, every family, every physician to contact their Congressmen and express their support for the Ovarian Cancer Biomarkers Research Act. It is quite literally -- and quite unfortunately -- a matter of life and death."

Adds Lindy Graham, an ovarian cancer survivor and advocate, "We absolutely need to pass this bill so our daughters, sisters, mothers, friends and neighborhood of women will finally be able to obtain early ovarian cancer detection that will ultimately save lives. No more sneak attacks from this disease!"

About SGO

The Society of Gynecologic Oncologists (SGO) is a national medical specialty society for physicians trained in the comprehensive management of women's cancers. The Society's membership is primarily comprised of gynecologic oncologists -- obstetrician/gynecologists who undertake an additional 3-4 years of intensive training in the specific study of gynecologic cancers. SGO members provide medical and surgical care to women with ovarian cancer, cervical cancer, endometrial cancer, vulvar cancer, and vaginal cancer. They are trained to in chemotherapy and radiation therapy administration, supportive care, and surgery in order to provide comprehensive care to their patients. More information on gynecologic oncology, the SGO, and its members can be found at http://www.sgo.org.

Contact: Jessica Schackmuth

Cell: (312) 235-4060


'/>"/>
SOURCE Society of Gynecologic Oncologists
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ovarian cancer in relationship with Hormone therapy
2. Vitamin D Reduces Chances of Colon, Breast And Ovarian Cancers by 50%
3. Progestin protects against ovarian cancer
4. Inherited gene important in ovarian cancer
5. Blood test may identify ovarian cancer
6. Exercise lowers Risk of Ovarian Cancer
7. Screening device for ovarian cancer
8. Ethnic discrepancy in ovarian cancer
9. Associated scan for detecting ovarian cancer spread
10. Gene Mutation Causes Ovarian Failure
11. Ovarian Cancer Screening Questioned
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... http://www.rebound-solution.com/ ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
Breaking Medicine Technology: